Compare SNT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNT | IFRX |
|---|---|---|
| Founded | 1965 | 2007 |
| Country | Canada | Germany |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 86.0M |
| IPO Year | 1993 | 2017 |
| Metric | SNT | IFRX |
|---|---|---|
| Price | $3.33 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 64.2K | ★ 6.5M |
| Earning Date | 11-25-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 257.88 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $37,837,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,075.42 |
| P/E Ratio | $13.70 | ★ N/A |
| Revenue Growth | ★ 9.82 | N/A |
| 52 Week Low | $2.57 | $0.71 |
| 52 Week High | $5.34 | $2.77 |
| Indicator | SNT | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.41 | 43.05 |
| Support Level | $2.75 | $0.92 |
| Resistance Level | $3.93 | $1.12 |
| Average True Range (ATR) | 0.37 | 0.10 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 31.27 | 39.73 |
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.